|Articles|June 2, 2003

Pharmaceutical Technology

  • Pharmaceutical Technology-06-02-2003
  • Volume 27
  • Issue 6

Formulation Development of a Nucleotide Phosphoramidate

A small-volume parenteral formulation of NB1011, an enzyme-catalyzed therapeutic activation compound, was successfully developed for intravenous administration.

Related to this article

CPHI Milan 2026: Trends in Pharma
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
FDA
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.